TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19041501

Group type: EXPERIMENTAL
Intervention: UVA light exposure with dry tattooing
Number of subjects: 20

Group type: COMPARATOR
Intervention: UVA light exposure without dry tattooing
Number of subjects: 20
Study: 15983534

Group type: EXPERIMENTAL
Intervention: Isoflavones (5 mg/kg body weight)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg) plus isoflavones (5 mg/kg body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12027856

Group type: EXPERIMENTAL
Intervention: Group LBH (2.5 ml lignocaine 2%, 2.5 ml bupivacaine 0.5%, 15 IU hyaluronidase/ml and 0.125 ml isotonic saline)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group LB (2.5 ml lignocaine 2%, 2.5 ml bupivacaine 0.5% and 0.125 ml isotonic saline)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group LBpH (2.5 ml lignocaine 2%, 2.5 ml bupivacaine 0.5% and 0.125 ml sodium bicarbonate 8.4%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group LBHpH (2.5 ml lignocaine 2%, 2.5 ml bupivacaine 0.5%, 15 IU hyaluronidase/ml and 0.125 ml sodium bicarbonate 8.4%)
Number of subjects: 60
Study: 10709307

Group type: EXPERIMENTAL
Intervention: Active stimulation consisting of pressure on acupoints (P)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Active stimulation consisting of stroking along the meridians (S)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control stimulation (C)
Number of subjects: 24
Study: 7795311

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nonpulsatile perfusion
Number of subjects: 38
Study: 1822997

Group type: EXPERIMENTAL
Intervention: 5 mg ISD (isosorbide dinitrate)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 111104

Group type: EXPERIMENTAL
Intervention: 1000 mg of slow-release xantinol nicotinate (XN) twice daily for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 31351832

Group type: EXPERIMENTAL
Intervention: Venefit
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: RFITT
Number of subjects: 180

Group type: COMPARATOR
Intervention: EVRF
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 180
Study: 28257982

Group type: EXPERIMENTAL
Intervention: Visual Search (VS) Attentional Bias Modification (ABM)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Visual Search (VS) Placebo-Training
Number of subjects: 108

Group type: COMPARATOR
Intervention: No-Training Control Group
Number of subjects: 108
Study: 26229189

Group type: EXPERIMENTAL
Intervention: Physician provision of early medical abortion
Number of subjects: 884

Group type: COMPARATOR
Intervention: Nurse provision of early medical abortion
Number of subjects: 884
Study: 23260628

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (30mL)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 140
Study: 20545775

Group type: EXPERIMENTAL
Intervention: DioxiDent mouthrinse
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Corsodyl mouthrinse
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tissue conditioner
Number of subjects: 60
Study: 19819667

Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine with 150U of recombinant human hyaluronidase (rHuPH20)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Subcutaneous morphine without recombinant human hyaluronidase (rHuPH20)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 18
Study: 16470116

Group type: EXPERIMENTAL
Intervention: HCV genotype 3
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Mean METAVIR fibrosis score
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: HCV viral load
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Ferritin
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: BMI and HCV viral load
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Mean METAVIR fibrosis score, BMI, and ferritin
Number of subjects: 395
Study: 15494907

Group type: EXPERIMENTAL
Intervention: Intravenous ribavirin (33 mg/kg followed by 16 mg/kg every 6 h for 4 days and 8 mg/kg every 8 h for 3 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (administered for 7 days or until negative Sin Nombre virus antibody test)
Number of subjects: 36
Study: 11069502

Group type: EXPERIMENTAL
Intervention: UVA sunbed treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo visible light exposure
Number of subjects: 38
Study: 9132126

Group type: EXPERIMENTAL
Intervention: diclofenac sodium 0.1%
Number of subjects: 99

Group type: COMPARATOR
Intervention: flurbiprofen 0.03%
Number of subjects: 99

Group type: COMPARATOR
Intervention: indomethacin 1.0%
Number of subjects: 99
Study: 8443028

Group type: EXPERIMENTAL
Intervention: metoprolol-Oros 14/190 once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: propranolol 80 mg twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: temazepam 10 mg once daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: metoprolol-Oros
Number of subjects: 12

Group type: COMPARATOR
Intervention: metoprolol-Oros and propranolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: temazepam
Number of subjects: 12
Study: 3533085

Group type: EXPERIMENTAL
Intervention: suprofen 200 mg/ml
Number of subjects: 87

Group type: COMPARATOR
Intervention: indoprofen 200 mg
Number of subjects: 87
Study: 30376097

Group type: EXPERIMENTAL
Intervention: OPV vaccination coverage at 70%
Number of subjects: 1652

Group type: EXPERIMENTAL
Intervention: OPV vaccination coverage at 30%
Number of subjects: 1652

Group type: EXPERIMENTAL
Intervention: OPV vaccination coverage at 10%
Number of subjects: 1652

Group type: COMPARATOR
Intervention: Household contacts of vaccinated subjects
Number of subjects: 1652

Group type: COMPARATOR
Intervention: Unvaccinated households
Number of subjects: 1652
Study: 27187447

Group type: EXPERIMENTAL
Intervention: Q‐Mix (1000 mg quercetin, 400 mg isoquercetin, 120 mg EGCG, 400 mg n3‐PUFAs, 1000 mg vitamin C, 40 mg niacinamide, 800 µg folic acid)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Q‐Mix
Number of subjects: 48
Study: 24421305

Group type: EXPERIMENTAL
Intervention: Whole information aid (IA) - group A (5 SIMS-Trial centres)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Take-home booklet/website component - group B (16 centres)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Whole information aid (IA) - group A
Number of subjects: 159

Group type: COMPARATOR
Intervention: Take-home booklet/website component - group B
Number of subjects: 159
Study: 22554876

Group type: EXPERIMENTAL
Intervention: Early postoperative physical therapy protocol (passive elevation and rotation starting at postoperative day 2)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Delayed postoperative physical therapy protocol (passive elevation and rotation starting at 6 weeks)
Number of subjects: 68
Study: 19468821

Group type: EXPERIMENTAL
Intervention: Plasma amino acids
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Urinary excretion of amino acids
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Amino acids in blood and urine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Gestational age‐matched reference values
Number of subjects: 80
Study: 16549375

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose, followed by 75 mg daily for 30 days)
Number of subjects: 67
Study: 15298642

Group type: EXPERIMENTAL
Intervention: Rapid immunochromatographic stool test before treatment
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Rapid immunochromatographic stool test after treatment
Number of subjects: 303
Study: 11380832

Group type: EXPERIMENTAL
Intervention: losartan 50 mg q.d. added to lisinopril 40 mg q.d. and other antihypertensive therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: lisinopril 40 mg q.d. and other antihypertensive therapy
Number of subjects: 16
Study: 9401940

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 6
Study: 8509590

Group type: EXPERIMENTAL
Intervention: Walking program (5 sessions per week for 12 weeks at 60% of heart rate reserve)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Calisthenics program (5 sessions per week for 12 weeks at 60% of heart rate reserve)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cross-sectional comparison of highly conditioned elderly women
Number of subjects: 30
Study: 3433015

Group type: EXPERIMENTAL
Intervention: Pentagastrin infusion (0.9 micrograms/kg/h, intravenously)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Sham feeding
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Atropine (0.7 and 7.0 micrograms/kg, intramuscularly) before sham feeding
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Atropine (0.0 micrograms/kg, intramuscularly) before pentagastrin
Number of subjects: 5
Study: 29732223

Group type: EXPERIMENTAL
Intervention: Mesh nebulizer with salbutamol inhalation solution (0.2 ml for children ≧ 2 years old)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Jet nebulizer with salbutamol inhalation solution (0.2 ml for children ≧ 2 years old)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Mesh nebulizer with salbutamol inhalation solution (0.1 ml for children < 2 years old)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Jet nebulizer with salbutamol inhalation solution (0.1 ml for children < 2 years old)
Number of subjects: 88
Study: 27757026

Group type: EXPERIMENTAL
Intervention: Vitamin E 50 mg/d for 5-8 years
Number of subjects: 7469
Study: 24679247

Group type: EXPERIMENTAL
Intervention: Intermittent Androgen Deprivation (IAD)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Continuous Androgen Deprivation (CAD)
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Number of subjects: 554
Study: 23369996

Group type: EXPERIMENTAL
Intervention: Health promotion intervention (three meetings, each lasting 1.5 hours)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Health promotion intervention
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 322
Study: 19684008

Group type: EXPERIMENTAL
Intervention: AREDS medication
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 18368070

Group type: EXPERIMENTAL
Intervention: ALL‐MB 91 (N=358)
Number of subjects: 713

Group type: COMPARATOR
Intervention: ALL‐BFM 90m (N=355)
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: ALL‐MB 91 (N=197)
Number of subjects: 713

Group type: COMPARATOR
Intervention: ALL‐BFM 90m (N=197)
Number of subjects: 713
Study: 16143681

Group type: EXPERIMENTAL
Intervention: Single subject research design
Number of subjects: 0
Study: 12772108

Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release (ECTR)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Open carpal tunnel release (OCTR)
Number of subjects: 123
Study: 11103174

Group type: EXPERIMENTAL
Intervention: Xenon (56%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isoflurane (0.8 MAC)
Number of subjects: 20
Study: 9282505

Group type: EXPERIMENTAL
Intervention: Sodium antimony gluconate (SAG) at a dose of 20 mg/kg/day up to a maximum of 850 mg/day for 4 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ketoconazole at a dose of 600 mg/day in 3 divided doses for 4 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Sodium antimony gluconate (SAG)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ketoconazole
Number of subjects: 180
Study: 8280551

Group type: EXPERIMENTAL
Intervention: i.v. ondansetron 4 mg
Number of subjects: 123

Group type: COMPARATOR
Intervention: metoclopramide 10 mg
Number of subjects: 123
Study: 3437450

Group type: EXPERIMENTAL
Intervention: Refusal skills training curriculum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent messages mailed to students' homes
Number of subjects: 0
Study: 29954606

Group type: EXPERIMENTAL
Intervention: Noninvasive high-frequency oscillatory ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (Control)
Number of subjects: 0
Study: 26408266

Group type: EXPERIMENTAL
Intervention: Icare rebound tonometry
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tonopen tonometry
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry
Number of subjects: 50
Study: 24559581

Group type: EXPERIMENTAL
Intervention: Early palliative care consultation and follow-up by a palliative care team
Number of subjects: 461

Group type: COMPARATOR
Intervention: Standard cancer care
Number of subjects: 461
Study: 23876566

Group type: EXPERIMENTAL
Intervention: Compassion‐Mindfulness Therapy (C‐MT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 82
Study: 20383847

Group type: EXPERIMENTAL
Intervention: epinastine
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: olopatadine
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: ketotifen
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: fluorometholone
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: naphazoline/antazoline
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: cromolyn sodium/chlorpheniramine maleate
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: diclofenac
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: levocabastine
Number of subjects: 240
Study: 18662492

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg QD
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg QD
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Duloxetine treatment
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 17405287

Group type: EXPERIMENTAL
Intervention: Multidisciplinary care (MDC)
Number of subjects: 129
Study: 12666950

Group type: EXPERIMENTAL
Intervention: Alendronate sodium (fosamax), one tablet every morning for six months
Number of subjects: 24

Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 24
Study: 11421377

Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil (AP) 1,000 mg + 400 mg once daily for 3 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Halofantrine (HF) 1,500 mg in 3 doses
Number of subjects: 48
Study: 8840413

Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg three times daily for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acyclovir 800 mg five times daily for 7 days
Number of subjects: 0
Study: 1643886

Group type: EXPERIMENTAL
Intervention: Almagate (0.25 to 0.5 mL/kg every 2 hrs by nasogastric tube)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ranitidine (1.5 mg/kg every 6 hrs iv)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Sucralfate (0.5 to 1 g every 6 hrs by nasogastric tube)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 140
Study: 6338251

Group type: EXPERIMENTAL
Intervention: Estramustine phosphate
Number of subjects: 124

Group type: COMPARATOR
Intervention: Cis-platinum
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Estramustine phosphate plus cis-platinum
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Combination therapy (estramustine phosphate plus cis-platinum)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 124
Study: 31381538

Group type: EXPERIMENTAL
Intervention: rTMS (10 Hz, 1200 pulses at 80% resting motor threshold)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 21
Study: 28420122

Group type: EXPERIMENTAL
Intervention: High-salt diet (18.0 g/day of NaCl)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-salt diet supplemented with potassium (18.0 g/day of NaCl + 4.5 g/day of KCl)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Low-salt diet (3.0 g/day of NaCl)
Number of subjects: 44
Study: 26054688

Group type: EXPERIMENTAL
Intervention: Prolonged capecitabine chemotherapy (1000mg/m² twice daily on days 1-14 of a 3-week cycle for eight cycles after eight cycles of XELOX)
Number of subjects: 307

Group type: COMPARATOR
Intervention: XELOX (oxaliplatin 130mg/m² on day 1 and oral capecitabine 1000mg/m² twice daily on days 1-14 of a 3-week cycle for eight cycles)
Number of subjects: 307
Study: 23803900

Group type: EXPERIMENTAL
Intervention: 7.5 μg dose of whole-virion inactivated H5N1 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15 μg dose of whole-virion inactivated H5N1 vaccine
Number of subjects: 0
Study: 21822058

Group type: COMPARATOR
Intervention: Normal isocaloric diet (balanced in fruits and vegetables)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Diet enriched in flavonoids and isothiocyanates (cruciferous vegetables)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Diet 1 supplemented with flavonoids (green tea and soy products)
Number of subjects: 88
Study: 19317862

Group type: EXPERIMENTAL
Intervention: Acceleromyography (AMG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mechanomyography (MMG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison of AMG and MMG
Number of subjects: 40
Study: 16512048

Group type: EXPERIMENTAL
Intervention: Conveen Optima urinary sheath
Number of subjects: 10

Group type: COMPARATOR
Intervention: Clear Advantage urinary sheath
Number of subjects: 10
Study: 15684845

Group type: EXPERIMENTAL
Intervention: Palliative care team recommendations
Number of subjects: 100
Study: 11453910

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with mTHPC (0.1 mg kg(‐1) intravenous injection) and light doses of 10 or 15 J cm(‐2) on days 1 or 2 after injection.
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with mTHPC (0.1 mg kg(‐1) intravenous injection) and light doses of 5-15 J cm(‐2).
Number of subjects: 187
Study: 9236900

Group type: EXPERIMENTAL
Intervention: Post-operative brachytherapy (BT) with a mean dose of 57 Gy (range: 50-60)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Post-operative external beam irradiation (EBI) with a mean dose of 50 Gy
Number of subjects: 68
Study: 8325311

Group type: EXPERIMENTAL
Intervention: 1.5 x 10(6) IU streptokinase over 60 min
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 30 U anistreplase over 5 min
Number of subjects: 125

Group type: COMPARATOR
Intervention: Both treatments (streptokinase and anistreplase)
Number of subjects: 125
Study: 2871787

Group type: EXPERIMENTAL
Intervention: Gastric Lavage (GL)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Ipecac-induced Emesis (IE)
Number of subjects: 88
Study: 31829725

Group type: EXPERIMENTAL
Intervention: Indoor exercise when Air Quality Health Index was ≥5
Number of subjects: 72

Group type: COMPARATOR
Intervention: Outdoor exercise every day (Control)
Number of subjects: 72
Study: 31605524

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training (n = 20)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 28333353

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir+lamivudine dual therapy
Number of subjects: 201

Group type: COMPARATOR
Intervention: Atazanavir/ritonavir-based triple therapy
Number of subjects: 201

Group type: COMPARATOR
Intervention: Comparison between dual therapy and triple therapy
Number of subjects: 201
Study: 26345959

Group type: EXPERIMENTAL
Intervention: DC-CIK therapy combined with docetaxel-cisplatin chemotherapy and synchronization conformal radiotherapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Docetaxel-cisplatin chemotherapy and synchronization conformal radiotherapy
Number of subjects: 63
Study: 24635460

Group type: EXPERIMENTAL
Intervention: Outpatient cervical priming
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Inpatient cervical priming
Number of subjects: 1004
Study: 22011308

Group type: EXPERIMENTAL
Intervention: Supervised exercise programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Start-up exercise programme
Number of subjects: 0
Study: 20078006

Group type: EXPERIMENTAL
Intervention: Barriers to research participation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potential solutions to research challenges
Number of subjects: 0
Study: 17035433

Group type: EXPERIMENTAL
Intervention: Pressure-relief CPAP (PRCPAP)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Constant CPAP
Number of subjects: 52
Study: 15319596

Group type: EXPERIMENTAL
Intervention: Dual-head coincidence gamma camera (DHC) with integrated X-ray transmission system
Number of subjects: 35

Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: DHC with integrated image fusion (FDHC)
Number of subjects: 35

Group type: COMPARATOR
Intervention: DHC compared to CT
Number of subjects: 35
Study: 12470180

Group type: EXPERIMENTAL
Intervention: DZP rectal gel
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 9564393

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both Propofol and Thiopentone
Number of subjects: 60
Study: 8082451

Group type: EXPERIMENTAL
Intervention: Intrauterine devices (IUD)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Non-IUD
Number of subjects: 285
Study: 2681022

Group type: EXPERIMENTAL
Intervention: International comparisons of patterns, trends, and determinants of CHD mortality
Number of subjects: 0
Study: 1161345

Group type: EXPERIMENTAL
Intervention: Calcium lactate, 800 mg/kg/24 hr in divided doses with each feed (group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No calcium supplement (group A)
Number of subjects: 30
Study: 31689708

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (160 U)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 15
Study: 30342026

Group type: EXPERIMENTAL
Intervention: Monopolar hemostatic forceps soft coagulation (MHFSC)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Hemoclips (HC)
Number of subjects: 112